Kiniksa Pharmaceuticals (KNSA)
(Delayed Data from NSDQ)
$22.35 USD
+0.74 (3.42%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $22.39 +0.04 (0.18%) 6:30 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Brokerage Reports
Kiniksa Pharmaceuticals, Ltd. [KNSA]
Reports for Purchase
Showing records 1 - 20 ( 110 total )
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Bucking Prior Guide; Setting a New 2024 Pace; Abiprubart Ready For Next Season
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Arcalyst Springing Forward; Abiprubart''s on the Clock
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Primed for Another Strong Year in RP; Waiting to See the River in RA
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Ruminating on KPL-404?s Prospects in Rheumatoid Arthritis
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KNSA 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Arcalyst Sees and Raises to the Top End; Looking For ?404 in Q1
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Bigger, Faster, Better, More! Arcalyst Strong Q1; 2023 Guidance Increased
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
A Strong Close to 2022 for Arcalyst, Continued Growth Ahead
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D